secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2023-03-13T23:59:59+00:00
Accession:  0001193125-23-068584
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharmaceuticals updates corporate presentation; no material new details disclosed
--------------------------------------------------------------------------------

- Filed a Form 8-K on March 13, 2023, to furnish an updated corporate presentation.
- Presentation highlights neffy as 'first no-needle, no-injection solution' for Type I allergic reactions.
- No financial, clinical, or regulatory milestones were reported in the filing or the title slide of Exhibit 99.1.
- Presentation is available on the company's website; content beyond the title slide is not provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312523068584/0001193125-23-068584-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312523068584/d444956d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-068584

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer